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Abstract 
Many biomarkers that could be used to assess ejection fraction, heart failure, or 
myocardial infarction fail to translate into clinical practice because they lack essential 
performance characteristics or fail to meet regulatory standards for approval. Despite their 
potential, new technologies have added to the complexities of successful translation into clinical 
practice. Biomarker discovery and implementation requires a standardised approach that 
includes: identification of a clinical need; identification of a valid surrogate biomarker; stepwise 
assay refinement, demonstration of superiority over current standard-of-care; development and 
understanding of a clinical pathway; and demonstration of real-world performance. Successful 
biomarkers should improve efficacy or safety of treatment, while being practical at a realistic 
cost. Everyone involved in cardiovascular healthcare, including researchers, clinicians, and 
industry partners, are important stakeholders in facilitating the development and implementation 
of biomarkers.  
This paper provides suggestions for a development pathway for new biomarkers, 
discusses regulatory issues and challenges, and suggestions for accelerating the pathway to 
improve patient outcomes. Real life examples of successful biomarkers–high sensitivity cardiac 
troponin (hs-cTn), T2* cardiovascular magnetic resonance (CMR) imaging, and 
echocardiography–are used to illustrate the value of a standardised development pathway in the 
translation of concepts into routine clinical practice.  
 
Keywords: biomarker, heart failure, myocardial infarction, pathway, troponin, ejection fraction, 
magnetic resonance 
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Introduction 
Through adoption of lifestyle modifications and evidence-based therapies, there has been 
considerable progress in reducing cardiovascular diseases (CVD) morbidity and mortality. 
However, cures for most CVD remain elusive and individual patient treatment responses are 
difficult to predict and may differ from those seen in randomised trials. Awareness that current 
approaches to diagnosis and management of CVD may be overly simplistic is driving interest in 
the potential of personalised medicine to improve clinical outcomes. Central to this process is a 
more precise approach to diagnosis that permits recognition of high-risk individuals at an early 
stage of disease, and better prediction of therapeutic responses. 
Evolving technologies in the fields of multi-omics (e.g. genomics, proteomics, 
metabolomics), clinical imaging, and data science further complicate the effort to discover new 
cardiovascular biomarkers that improve the understanding of disease, translate into novel 
therapeutic targets, and lead to new instruments for predicting and monitoring treatment 
responses. The aim of this round table meeting, and this document, is to provide an overview of 
the development, validation, and implementation of new biomarkers in clinical practice. 
 
What is a biomarker? 
Biomarkers are variously defined. The European Medicine Agency (EMA) defines a 
biomarker as “A biological molecule found in blood, other body fluids, or tissues that can be 
used to follow body processes and diseases in humans and animals.”1 The World Health 
Organization (WHO) suggests that a biomarker is “almost any measurement reflecting an 
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5 
interaction between a biological system and a potential hazard, which may be chemical, physical, 
or biological.”2 
There is some controversy on whether biomarkers should include only molecules 
circulating in the blood (sometimes referred to as “wet biomarkers”) or encompass clinical 
characteristics and non-invasive measures such as medical imaging, electrocardiography and 
blood pressure measurement. In oncology, molecules measured in tissue biopsies are commonly 
used, but this is rare in CVD. In CVD, the more comprehensive definition of biomarkers that 
includes circulating molecules and imaging parameters, as well as all relevant measurable 
clinical characteristics is more usual.  
Using this broad definition, reports of cardiovascular biomarkers in the medical literature 
can be counted in the thousands, but the number of biomarkers used routinely in clinical practice 
is remarkably small.3, 4 The explanations may include an incomplete or superficial understanding 
of disease pathophysiology, or variability in test availability and utilisation. A poor appreciation 
of the development pathway leading to clinically actionable biomarkers is often a major barrier 
to successful implementation. 
 
Development pathway for new biomarkers 
Biomarker discovery and implementation often involves use of big data, data mining, 
systems biology, and reverse translational research, but a detailed description of these areas is 
beyond the scope of this article.  
In sharp contrast with oncology, the validation of biomarkers as surrogates for 
therapeutic efficacy and safety remains unsatisfactory in cardiovascular medicine. The reality is 
that very few putative biomarkers make it into routine practice. The reasons for this are varied, 
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but almost certainly include incomplete understanding of the complex pathophysiology of CVD 
and a reductionist approach to the diagnosis of common phenotypes such as heart failure and 
hypertension. Indeed, the use of biomarkers often reveals gaps in knowledge when applied to 
real life scenarios.  
The group agreed that most cardiac biomarkers fail to translate into clinical practice 
because of a poor appreciation of the essential performance characteristics of biomarkers and the 
rigor required in their identification, testing, and validation. This is particularly true of many 
‘omic’ markers where discovery is often acclaimed before consideration of the clinical potential 
or relevance. 
The group identified a list of attributes shared by successful biomarkers and suggested  an 
ideal development pathway that, if considered from the outset, might improve the chance of 
successful translation (Figure 1). Of particular importance is the requirement that successful 
biomarkers, or indeed any diagnostic technique, must meet clearly defined clinical needs and 
their use must be demonstrated to improve the efficacy or the safety of patient management. In 
addition, biomarkers should show superiority over current standards of care (SOC)–something 
that is rarely demonstrated–and be practical and scalable using validated reproducible 
technologies at a realistic cost. Ideally biomarkers should be based on the assay of easily 
accessible tissues (blood or urine) or on non-invasive physiological measurements (ultrasound, 
magnetic resonance). 
The ideal characteristics of a biomarker depend in part on the intended use. In the context 
of personalised medicine, distinction may be drawn between prognostic, predictive, and 
pharmacodynamic markers. Prognostic biomarkers assess the likely course of a disease with or 
without therapy and predictive biomarkers identify individuals who are more likely to respond to 
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a given specific or targeted therapy. Pharmacodynamic biomarkers measure the effect of a drug 
on the disease state itself. Table 1 illustrates some of the ideal characteristics of biomarkers 
designed for use in screening, diagnosis, or prognostic assessment.5 
 
Regulatory process and challenges 
In Europe, licensing of new biomarkers is in the form of a CE-Mark, which is granted by 
groups called Notified Bodies. Licensing is mandatory for all products (including devices and 
biomarkers) available in the European Economic Area (EEA). The CE-Mark indicates that the 
product conforms to the requirements of the In Vitro Diagnostic Devices (IVD) Directive 
(98/79/EC). This is being replaced by the IVD Regulation (2017/746)] which makes clinical 
performance data and scientific validity reports mandatory (including benefit/risk analysis and 
periodic safety and clinical performance reports), in addition to analytical performance data.6 For 
imaging biomarkers that use analysis software, the software “device” should be built within a 
specific regulatory framework to meet the appropriate standards (i.e. under ISO13485 and other 
standards). The EMA provides support for qualification of innovations used in research and 
development of pharmaceuticals.7 The Committee for Medicinal Products for Human Use 
(CHMP) provides an opinion on the acceptability of a novel methodology or imaging method for 
a specific use (non-clinical or clinical studies). The CHMP may also provide advice for further 
development towards qualification.  
The requirements for accepting a biomarker in the regulatory field of drug development 
depend on the intended use and context, for example: proof of concept, dose finding, 
characterisation of safety, or a phase III clinical trial. Considerations in the development of a 
biomarker for clinical use from a regulatory perspective are shown in Table 2. 
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Companion diagnostics play an important role in regulatory approval. A companion 
diagnostic is a device or bioassay that is essential for the use of a medicinal product. If the 
labelling of a medication recommends that it should be used in conjunction with a predictive 
biomarker, the commercial assay will require a CE-mark. The challenge is to demonstrate that 
the companion diagnostic used to select patients is accurate and validated, and that patients are 
neither deprived of efficacious therapy nor exposed to harm. 
 
Examples of successful cardiovascular biomarkers 
In spite of more than 50,000 PubMed entries on cardiac biomarkers over the past 20 years 
and large investments from the private and public sector, the number of novel cardiovascular 
biomarkers approved as blood tests or imaging markers that have been adopted into clinical 
practice is extremely small. Moreover, the evidence supporting some of the biomarkers that are 
used in routine practice is relatively weak. The reasons for this unsatisfactory state of affairs are 
many and include the considerable investment necessary to meet regulatory requirements,8 the 
often poor intellectual property and reimbursement opportunities, and the inability to file patents 
on new markers. However, many putative markers also fail to meet the fundamental standards 
advocated in this document. To illustrate what can be achieved if a systematic approach is 
followed, we consider three examples–high sensitivity cardiac troponin (hs-cTn), T2* 
cardiovascular magnetic resonance (CMR) imaging and echocardiography–and show how their 
development into clinically useful biomarkers can be viewed in the context of the suggested 
development pathway (Figure 1). These are summarized in Figure 2. 
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hs-cTn 
I. Clinical need: The clinical needs for a hs-cTn were 3-fold: 1) electrocardiogram 
(ECG) did not detect 50% of the acute myocardial infarctions (AMIs); 2) existing markers (CK-
MB; myosin) were not specific to the heart; and 3) alterations in existing markers (CK-MB; 
myosin) were not rapid enough to detect early changes. 
II. Identification of a biomarker: Cardiac troponins were identified in the 1980s but it 
was not until the 1990s that cTnT and I assays were introduced into clinical practice.9-12 By 
2009, the tests were technically advanced enough to measure the marker in healthy individuals 
(“high sensitive”). Clinical studies demonstrated that measurement of cTn improved sensitivity 
and specificity for the diagnosis of myocardial infarction9, 10 and that cTn is a predictor of 
mortality.13-16 However, the original cTn assay had some limitations, most notably low 
sensitivity in the first hours of AMI, which resulted in delayed diagnosis and treatment.17 It was 
recognised that the ability to accurately detect lower cTn concentrations would substantially 
shorten the time to diagnosis.18-20 Consequently, new high-sensitivity assays were developed 
from 2009 onwards. 
III. Superiority over SOC: In large cohort studies, hs-cTn has demonstrated superior 
sensitivity and specificity over conventional cTn assays for the early diagnosis of AMI, 
especially when compared to markers such as myosin, CK-MB, and also ECG.19, 20 Such 
important observations led to a new definition of the disease, where troponins played a central 
part (e.g. non-ST segment elevation MI [NSTEMIs]). The implementation into clinical practice 
led to a higher proportion of patients benefiting from care, and to a reduction of the ESC 
recommended observation time for AMI from 6 to 3 hours in 2011, and from 3 to 1 hour in 2015, 
which has led to cost savings and reduced length of stay in emergency rooms.21 Hs-cTn has also 
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demonstrated benefits in terms of prognosis and response to therapy. In treatment trials, for 
example those with P2Y12 inhibitors, a reduced risk of CVD events was shown in patients with 
NSTEMI and elevated hs-cTnT levels but not in those with negative hs-cTnT.22 
IV. Development of a clinical pathway: A validated, clinical assay has been developed 
for hs-cTn. The European Society of Cardiology (ESC) algorithm incorporating baseline values 
and absolute changes in hs-cTnT within the first hour that safely and accurately ruled-in AMI 
within 1 hour in 77% of unselected patients with acute chest pain.23 This was prospectively 
validated in the Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE),24 
and the High Sensitivity Cardiac Troponin T assay for Rapid Rule-out of Acute Myocardial 
Infarction (TRAPID-AMI) studies, with the later focusing on the particularly demanding early 
presenters.25 
Widespread implementation in routine clinical practice has been facilitated by integration 
of cTn into the ESC guidelines since 2002,26 and hs-cTn since 2011.27 
V. Real world performance: Real-world cohort data have demonstrated the utility of hs-
cTn in clinical practice. In a retrospective analysis of the SWEDEHEART registry, the switch 
from to hs-cTnT from cTnT was shown to be more effective for risk prediction, and to guide 
appropriate treatment.28 In addition, the use of the ESC 0/1-h algorithm has been assessed in 
prospective studies.24, 29-31 In one study, the algorithm assigned 62% of patients to the rule-out 
and 13% to the rule-in groups. The safety of rule-out was very high with a 30-day major adverse 
cardiac event (MACE) incidence of 0.2%.29  
Summary: While hs-cTn is an example of a successfully implemented biomarker, 
biomarker for myocardial infarction, one of the early barriers to implementation was a perception 
that the previous gold standard of CK-MB was adequate. In addition, political and regulatory 
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barriers contributed to slow implementation because of lack of initial reimbursement for the 
newer marker. 
T2* CMR 
I. Clinical need: Thalassaemia major is a genetic disorder in which ineffective 
erythropoiesis results in severe anaemia.32 Patients require lifelong transfusions, which can lead 
to iron overload and cardiomyopathy, with heart failure being the leading cause of death.32, 33 
The cardiomyopathy is reversible with early treatment, but diagnosis is often delayed due to 
unpredictable iron deposition and late-onset symptoms.33, 34 
II. Identification of a biomarker: T2* CMR measures T2* relaxation, which is the rate 
of decay of magnetisation in the presence of in-homogeneities of the magnetic field, including 
those caused by iron deposition.35 Septal T2* has been proven to be representative of the mean 
total cardiac iron concentration.36 T2* CMR for tissue iron quantification was made available in 
1990.37 
III. Superiority over SOC: Myocardial iron deposition was shown to reproducibly, 
correlate with myocardial T2*, but not with serum ferritin or liver iron, which can only detect 
advanced disease.33, 38 T2* was highly predictive of cardiac complications.33, 38 Randomised 
controlled trials of iron chelation in thalassaemia patients have shown that improvement in 
myocardial T2* correlates with improvement in left ventricular ejection fraction (LVEF).39, 40 
IV. Development of a clinical pathway: Studies have shown that very low cardiac T2* 
<10 ms was highly predictive of cardiac events.38, 41 A 3-tier risk model has been developed to 
define the risk of iron overload.32 Cardiac T2* measurements for diagnosis and to guide 
treatment have now been incorporated into clinical practice guidelines for β-thalassaemia 
major.32 
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V. Real world performance: Registry data from the UK showed a remarkable 71% 
reduction in the mortality rate due to iron overload after 1999.42 This was most likely related to 
the introduction of T2* CMR and appropriate early use of iron chelation therapy. 
Summary: T2* CMR was developed and validated in the early 2000s.33 Unlike hs-cTn, 
there was rapid uptake into clinical practice. This may have been driven by the poor performance 
of traditional methods for the diagnosis of cardiac iron overload, technical developments in 
CMR, and the continuing high morbidity and mortality despite chelation therapy.43 In addition, 
hs-troponin is a marker for the most frequent of all cardiac diseases, while T2* CMR is a marker 
for a quite rare cardiac disease. 
Left Ventricular Ejection Fraction 
I. Clinical need: Left ventricular (LV) systolic performance is impaired in many CVD 
and has been repeatedly shown to be a marker of adverse prognosis. Consequently, in heart 
failure with reduced ejection fraction (HFrEF), many therapies, including pharmacological, 
interventional, and device-based, aim to improve LV function. Accordingly, there is a need for 
standardised, precise, and reproducible methods to measure this parameter.  
II. Identification of a biomarker: LVEF defined as: “(LV end-diastolic volume –LV 
end-systolic volume) divided by LV end-diastolic volume”, can be assessed using different 
imaging modalities including invasive left ventriculography, two-dimensional echocardiography 
(intravenous contrast and three-dimensional echocardiography improve accuracy), ECG-gated 
imaging radionuclide ventriculography with single-photon emission computed tomography or 
positron emission tomography, CMR imaging, and computed tomography. The various methods 
have different performances; two-dimensional echocardiography being the least reproducible but 
least costly and most often used in daily clinical practice. 
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III. Superiority over SOC: In most major HFrEF outcome trials, LVEF is strongly 
related to mortality, and morbidity (e.g. heart failure). In addition, changes in LVEF after 
medical or device therapy have been related to improved survival and symptoms. Changes over 
time, or before versus after treatment are related to long-term outcomes.  
IV. Development of a clinical pathway: In almost all heart failure guidelines from the 
ESC, LVEF is included as the main marker of LV function (and changes in LV function) and 
considered a strong prognostic marker in HFrEF. In most ESC guidelines assessment of LVEF 
has a class I recommendation (“must do”), with level of evidence A (supported by 1 or more 
randomized clinical trials or meta-analyses) (e.g. in the STEMI,44 non-STEMI,27, heart failure,45 
and valvular heart disease guidelines46). 
V. Real world performance: Large real-world outcome registries on CVD have 
confirmed the strong prognostic value of LVEF in patients with LV systolic dysfunction. 
Similarly, registries on different cardiovascular therapies have shown the strong prognostic value 
of change in LVEF.  
Summary: LVEF is the standard measure of LV function with varying degrees of 
accuracy and reproducibility, depending on the imaging technique. All non-invasive imaging 
techniques can measure LVEF. Particularly in HFrEF, this imaging biomarker provides strong 
prognostic information. 
 
Accelerating the pathway to improve patient outcomes 
Everyone involved in CVD healthcare is a potentially important contributor to the 
development and implementation of biomarkers, with the goal of improving patient care (Table 
3). For example, researchers and clinicians who identify and investigate the utility of new 
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biomarkers, and the industry partners who develop and market the biomarker assays to a wider 
audience, all play an important role. The ESC and similar organisations can facilitate assessment 
of clinical needs, knowledge sharing, and data collection. They can also drive change through 
clinical practice guidelines, standardisation, and interaction between researchers, industry, 
regulatory bodies, and community clinicians. 
One of the main barriers to biomarker implementation is the behaviour of clinicians 
themselves. The concept of clinical or therapeutic “inertia” defined as a failure to initiate or 
intensify therapy in spite of clear guidance is an increasingly recognised determinant of patient 
outcomes.47, 48 The causes of clinical inertia are complex, including patient characteristics such 
as older age, poor life expectancy and multiple comorbidities, and healthcare provider attributes 
such as lack of knowledge, workload, and individual attitudes or beliefs about risk tolerance and 
uncertainty. The same factors influence uptake of biomarkers and emphasise the importance of 
key specialists in securing regulatory approvals, guideline placement, and uptake into clinical 
practice. Clinicians also need supporting infrastructures to assist them with knowledge transfer 
and application in front-line medicine. Information networks and other mechanisms that facilitate 
communication of knowledge about biomarkers, advances in biomarker research, or evidence of 
their clinical utility are still in their infancy, but are recognised as a major priority in personalised 
medicine.49 
To be used in clinical practice, a biomarker must first obtain licensing and regulatory 
approval. In line with this is the need to obtain reimbursement of the test. The availability and 
cost of assays can be barriers; development and validation of a new biomarker is often hindered 
by the lack of a validated SOC. 
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Future opportunities  
Prevention of CVD depends on the ability to recognize high-risk individuals at an early 
stage of disease long before the development of adverse events. Evolving technologies in the 
fields of genomics, proteomics, metabolomics and clinical imaging are playing a significant role 
in the discovery of cardiovascular biomarkers and in the understanding of disease 
pathophysiology.  
The rapid development of the field of artificial intelligence (AI) has created new 
opportunities but also new challenges in the development and validation of novel biomarkers. 
Machine learning (ML) is currently used in the form of supervised or unsupervised learning in 
order to predict a given value or class.50 Deep learning is commonly used for pattern recognition 
and classification, mimicking human cognition by using convolutional neural networks; these 
networks are characterized by the ability to learn based on prior experience, simulating human-
like decision making.50 ML can be used either to facilitate the measurement of a known 
biomarker in a faster and more accurate way (e.g. in measuring LVEF51) or to discover novel 
biomarkers. For example, the Fat Attenuation Index (FAI) is an AI-powered method that 
quantifies coronary inflammation by analysing non-visible patterns within pericoronary fat in 
standard coronary CT angiography, and has striking prognostic value in external validation 
clinical cohorts.52, 53 Similarly, pattern recognition using ML has the power to detect subclinical 
atrial fibrillation and predict stroke, from ECGs of patients on sinus rhythm.54 
The development of such biomarkers however, needs to be strictly regulated to ensure 
their accuracy, reproducibility, and generalizability. The size and heterogeneity of the training 
dataset is crucial, to be representative of the population where the biomarker will be applied. To 
avoid data over-fitting, true external validation into completely independent cohorts is essential. 
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As many of these AI algorithms follow a “black box” approach, independent validation is often 
not possible. But the biggest challenge comes when these biomarkers include a real-time, self-
learning algorithm. Currently the regulators (and particularly the FDA) do not feel comfortable 
with real-time self-learning biomarkers, and they require “off line” improvement and re-approval 
of an updated algorithm version. However, this is expected to change in the near future. There is 
a wave of AI technologies heading towards clinical adoption, and a new framework is needed for 
their assessment, approval and prospective monitoring. 
Most cardiology practice is based on simplified functional diagnoses (e.g. HFrEF and 
heart failure with preserved ejection fraction), but the emergence of personalised medicine as a 
goal of modern medical practice offers new possibilities for therapeutic innovation. Biomarker 
discovery and implementation depend on collaborative efforts and must be founded on 
actionable, quantifiable clinical information that can be easily, rapidly, and correctly used to 
identify novel therapeutic targets, modifiable risk factors, and monitoring markers – all under 
pressure of providing value for money. It is crucial that more effort be made to ensure that 
putative biomarkers are subjected to prospective clinical trials to determine their impact on 
clinical outcomes. This approach will only work if it is patient centred, data driven and value 
based. 
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Figure legends 
Figure 1: Pathway from discovery to implementation of a new biomarker 
 
Figure 2: Summary of examples of clinically useful biomarkers that have been systematically 
developed in the context of the suggested pathway shown in Figure 1  
AMI, acute myocardial infarction; CK, creatinine kinase; CMR, cardiovascular magnetic resonance; ECG, 
electrocardiogram; Fe, iron; hs-cTnT, high sensitivity cardiac troponin, LVEF, left ventricular ejection fraction; 
SOC, standard of care 
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Appendices 
Appendix 1. Additional participants 
Dan Atar (University of Oslo), Agim Beshiri (Abbott), Anders Gabrielsen (Astra Zeneca), 
Michael Glikson (Shaare Zedek Medical Center), Alexandra Goncalves (Philips), Christer 
Gottfridsson (Astra Zeneca), Anders Himmelmann (Astra Zeneca), Claudia Kaiser-Albers 
(MSD), Matthias Langenfeld (Amgen), Sophie Nisse-Durgeat (Servier International), Philippa 
Pettingill (Olink Proteomics), Gerald Poetzsch (Philips), Cesare Russo (Novartis Pharma AG), 
Stephan Schwers (Bayer AG), Richard Urquhart (Boehringer-Ingelheim), Nadja Walder (Vifor 
Pharma) 
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Text tables 
Table 1: Ideal characteristics of biomarkers designed for use in screening, diagnosis, or 
prognostic assessment 
Intended use  
of biomarker 
Ideal characteristics 
Screening 
 High specificity 
 Known reference values 
 Incremental value above existing markers 
 Implications for therapeutic or lifestyle interventions 
 Low cost 
Prognosis 
 High specificity 
 Low intra-individual variability 
 Adds to known prognostic indicators/models 
 Responds to therapy and predicts treatment success 
Diagnosis 
 High sensitivity 
 Therapeutic implications 
 Low cost 
Adapted from reference.5 
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Table 2: Regulatory issues to consider when developing a biomarker for clinical use 
Requirements Examples 
 Demonstrate the technical, preclinical, and 
clinical validation of the biomarker 
 Sensitivity, specificity, ROC curve 
analyses 
 Demonstrate clinical utility  Impact of using a biomarker on 
benefit:risk ratio of a medication 
 Demonstrate stability of biomarker  Time/patient characteristics, impact of a 
medication on the biomarker 
ROC, receiver operating characteristic 
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Table 3: Priorities for improving the pace of development and implementation of 
cardiovascular biomarkers 
1. Identify, and prioritise unmet clinical needs that can be solved with novel biomarkers 
2. Identify robust biomarkers candidates using a systematic approach (Figure 1) 
3. Promote exchange of information among researcher groups, regulatory bodies, industry, 
and community clinicians, by relevant bodies including the ESC to critically explore the 
clinical value of these biomarker  
4. Develop and support central knowledge exchange platforms (e.g. central registry/biobank 
data collection) to drive standards in biomarker research 
5. Focus clinical practice guidelines on unmet needs and potential solutions 
6. Encourage interaction between key stakeholders, research funders and regulators  
7. Develop and regularly update a database of industry resources, such as contact 
information, and funding/grant availability 
8. Provide education and training to scientists and clinicians to improve the understanding of 
biomarkers and facilitate rapid implementation of new biomarkers into clinical practice 
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